Sepsis: from bench to bedside

Sepsis is a syndrome related to severe infections. It is defined as the systemic host response to microorganisms in previously sterile tissues and is characterized by end-organ dysfunction away from the primary site of infection. The normal host response to infection is complex and aims to identify...

Full description

Bibliographic Details
Main Authors: Eliézer Silva, Rogério Da Hora Passos, Maurício Beller Ferri, Luiz Francisco Poli de Figueiredo
Format: Article
Language:English
Published: Faculdade de Medicina / USP 2008-01-01
Series:Clinics
Subjects:
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322008000100019
id doaj-8de3db543ad74e149f7417b1477136ba
record_format Article
spelling doaj-8de3db543ad74e149f7417b1477136ba2020-11-24T22:11:37ZengFaculdade de Medicina / USPClinics1807-59321980-53222008-01-0163111012010.1590/S1807-59322008000100019Sepsis: from bench to bedsideEliézer SilvaRogério Da Hora PassosMaurício Beller FerriLuiz Francisco Poli de FigueiredoSepsis is a syndrome related to severe infections. It is defined as the systemic host response to microorganisms in previously sterile tissues and is characterized by end-organ dysfunction away from the primary site of infection. The normal host response to infection is complex and aims to identify and control pathogen invasion, as well as to start immediate tissue repair. Both the cellular and humoral immune systems are activated, giving rise to both anti-inflammatory and proinflammatory responses. The chain of events that leads to sepsis is derived from the exacerbation of these mechanisms, promoting massive liberation of mediators and the progression of multiple organ dysfunction. Despite increasing knowledge about the pathophysiological pathways and processes involved in sepsis, morbidity and mortality remain unacceptably high. A large number of immunomodulatory agents have been studied in experimental and clinical settings in an attempt to find an efficacious anti-inflammatory drug that reduces mortality. Even though preclinical results had been promising, the vast majority of these trials actually showed little success in reducing the overwhelmingly high mortality rate of septic shock patients as compared with that of other critically ill intensive care unit patients. Clinical management usually begins with prompt recognition, determination of the probable infection site, early administration of antibiotics, and resuscitation protocols based on "early-goal" directed therapy. In this review, we address the research efforts that have been targeting risk factor identification, including genetics, pathophysiological mechanisms and strategies to recognize and treat these patients as early as possible.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322008000100019SepsisShockInfectionOrgan DysfunctionOrgan Failure
collection DOAJ
language English
format Article
sources DOAJ
author Eliézer Silva
Rogério Da Hora Passos
Maurício Beller Ferri
Luiz Francisco Poli de Figueiredo
spellingShingle Eliézer Silva
Rogério Da Hora Passos
Maurício Beller Ferri
Luiz Francisco Poli de Figueiredo
Sepsis: from bench to bedside
Clinics
Sepsis
Shock
Infection
Organ Dysfunction
Organ Failure
author_facet Eliézer Silva
Rogério Da Hora Passos
Maurício Beller Ferri
Luiz Francisco Poli de Figueiredo
author_sort Eliézer Silva
title Sepsis: from bench to bedside
title_short Sepsis: from bench to bedside
title_full Sepsis: from bench to bedside
title_fullStr Sepsis: from bench to bedside
title_full_unstemmed Sepsis: from bench to bedside
title_sort sepsis: from bench to bedside
publisher Faculdade de Medicina / USP
series Clinics
issn 1807-5932
1980-5322
publishDate 2008-01-01
description Sepsis is a syndrome related to severe infections. It is defined as the systemic host response to microorganisms in previously sterile tissues and is characterized by end-organ dysfunction away from the primary site of infection. The normal host response to infection is complex and aims to identify and control pathogen invasion, as well as to start immediate tissue repair. Both the cellular and humoral immune systems are activated, giving rise to both anti-inflammatory and proinflammatory responses. The chain of events that leads to sepsis is derived from the exacerbation of these mechanisms, promoting massive liberation of mediators and the progression of multiple organ dysfunction. Despite increasing knowledge about the pathophysiological pathways and processes involved in sepsis, morbidity and mortality remain unacceptably high. A large number of immunomodulatory agents have been studied in experimental and clinical settings in an attempt to find an efficacious anti-inflammatory drug that reduces mortality. Even though preclinical results had been promising, the vast majority of these trials actually showed little success in reducing the overwhelmingly high mortality rate of septic shock patients as compared with that of other critically ill intensive care unit patients. Clinical management usually begins with prompt recognition, determination of the probable infection site, early administration of antibiotics, and resuscitation protocols based on "early-goal" directed therapy. In this review, we address the research efforts that have been targeting risk factor identification, including genetics, pathophysiological mechanisms and strategies to recognize and treat these patients as early as possible.
topic Sepsis
Shock
Infection
Organ Dysfunction
Organ Failure
url http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322008000100019
work_keys_str_mv AT eliezersilva sepsisfrombenchtobedside
AT rogeriodahorapassos sepsisfrombenchtobedside
AT mauriciobellerferri sepsisfrombenchtobedside
AT luizfranciscopolidefigueiredo sepsisfrombenchtobedside
_version_ 1725804882635522048